SAN DIEGO (360Dx) — A new laboratory-developed assay that more accurately measures platelet binding activity of von Willebrand factor (VWF) in patients is now available for the first time in the US, offering a potentially more accurate diagnosis, as well as better treatment, for von Willebrand disease.
BloodCenter of Wisconsin Offers New Type of Test in US to Accurately Diagnose von Willebrand Disease
Premium
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.